Summit Trail Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,688 shares of the company’s stock after acquiring an additional 592 shares during the quarter. Summit Trail Advisors LLC’s holdings in Johnson & Johnson were worth $2,065,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson in the 4th quarter worth $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $48,000. VitalStone Financial LLC bought a new position in Johnson & Johnson in the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC raised its holdings in Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares during the period. 67.94% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Raymond James cut their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Guggenheim initiated coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same quarter in the previous year, the firm posted $2.67 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.93%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 5/1 – 5/5
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
